MARUCCI, Gabriella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.915
EU - Europa 9.287
AS - Asia 6.760
SA - Sud America 878
Continente sconosciuto - Info sul continente non disponibili 579
AF - Africa 262
OC - Oceania 19
Totale 38.700
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.266
CN - Cina 2.742
SG - Singapore 1.963
RU - Federazione Russa 1.852
IT - Italia 1.624
PL - Polonia 1.548
DE - Germania 1.135
BR - Brasile 718
GB - Regno Unito 666
FR - Francia 571
HK - Hong Kong 550
UA - Ucraina 509
SE - Svezia 506
VN - Vietnam 502
CA - Canada 501
FI - Finlandia 351
TR - Turchia 242
KR - Corea 212
ZA - Sudafrica 172
IE - Irlanda 128
IN - India 123
JP - Giappone 101
BE - Belgio 81
NL - Olanda 78
MX - Messico 72
EU - Europa 71
AR - Argentina 67
BD - Bangladesh 49
CZ - Repubblica Ceca 41
ES - Italia 41
IR - Iran 38
PK - Pakistan 35
IQ - Iraq 30
EC - Ecuador 28
RO - Romania 23
AT - Austria 22
ID - Indonesia 19
AE - Emirati Arabi Uniti 18
CO - Colombia 18
TW - Taiwan 18
CH - Svizzera 16
EG - Egitto 16
KE - Kenya 16
CR - Costa Rica 15
HN - Honduras 15
AU - Australia 14
MA - Marocco 14
LT - Lituania 13
RS - Serbia 13
EE - Estonia 12
JO - Giordania 12
PE - Perù 12
SA - Arabia Saudita 12
VE - Venezuela 12
IL - Israele 11
JM - Giamaica 11
PY - Paraguay 11
TN - Tunisia 11
UZ - Uzbekistan 11
AZ - Azerbaigian 10
PH - Filippine 8
TT - Trinidad e Tobago 8
CL - Cile 7
LB - Libano 7
MY - Malesia 7
NI - Nicaragua 7
AM - Armenia 6
BG - Bulgaria 6
CI - Costa d'Avorio 6
HR - Croazia 6
OM - Oman 6
TH - Thailandia 6
AL - Albania 5
BY - Bielorussia 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
GR - Grecia 5
SC - Seychelles 5
DK - Danimarca 4
GE - Georgia 4
HU - Ungheria 4
NO - Norvegia 4
NP - Nepal 4
PT - Portogallo 4
BS - Bahamas 3
ET - Etiopia 3
GT - Guatemala 3
KW - Kuwait 3
KZ - Kazakistan 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
BB - Barbados 2
BO - Bolivia 2
CW - ???statistics.table.value.countryCode.CW??? 2
KH - Cambogia 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
Totale 38.163
Salva come PNG Salva come JPEG
Città #
Ashburn 1.804
Fairfield 1.493
Woodbridge 1.483
Dallas 1.354
Jacksonville 1.211
Warsaw 1.198
San Jose 1.086
Singapore 1.007
Chandler 948
Houston 819
Council Bluffs 714
Ann Arbor 709
Wilmington 697
Seattle 641
Cambridge 543
Hong Kong 514
Boardman 513
Beijing 459
Nanjing 409
Kraków 331
Los Angeles 304
Toronto 304
New York 268
The Dalles 266
Camerino 246
Columbus 191
Istanbul 191
San Mateo 185
Seoul 183
Düsseldorf 178
Helsinki 172
Tongling 167
Princeton 166
Lawrence 163
Ho Chi Minh City 162
Dearborn 158
Johannesburg 154
Santa Clara 152
Lauterbourg 144
Ogden 138
Moscow 133
Chicago 128
London 128
Dublin 126
Nanchang 125
Buffalo 124
Milan 120
Lachine 117
Shanghai 112
Munich 105
Hanoi 101
Guangzhou 99
Phoenix 96
São Paulo 96
Kunming 86
Tokyo 82
San Diego 76
Brussels 75
Shenyang 67
Tianjin 65
Frankfurt am Main 63
Orem 63
Jiaxing 62
Hebei 61
St Louis 56
Rome 52
Hangzhou 45
Edinburgh 44
Washington 44
Philadelphia 42
Denver 40
Wuhan 39
Centro 37
San Francisco 37
Brooklyn 36
Venezia 36
Changsha 35
Chennai 35
Ningbo 35
Hefei 32
Atlanta 31
Dong Ket 31
Redwood City 31
Mexico City 30
Boston 29
Poplar 29
Stockholm 29
Turku 29
Brno 28
Jinan 27
Manchester 27
Da Nang 26
Falls Church 26
Montreal 26
Perugia 26
Trieste 26
Venice 26
Orange 25
Newark 24
Norwalk 24
Totale 25.330
Salva come PNG Salva come JPEG
Nome #
1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: Structure-affinity/activity relationship at α1-adrenoceptor subtypes and at 5-HT1A receptors. 625
1,2,4-Benzothiadiazine derivatives as alpha1 and 5-HT1A receptor ligands 620
“1,3 Oxathiolane Muscarinic Ligands Modified at the Cationic Head”. 580
1,3-Dioxolane-based ligands as a novel class of alpha(1)-adrenoceptor antagonists 547
1,3-Dioxolane-based ligands as rigid analogues of Naftopidil: structure-affinity/activity relationships at alpha1 and 5-HT1A receptors. 539
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 468
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 424
Overview on Radiolabel-Free in Vitro Assays for GPCRs 415
Pharmacological characterization of the GPR17 receptor dual profile 413
GPR17 receptor modulators and their therapeutic implications: review of recent patents 411
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 396
The G Protein-Coupled Receptor GPR17: Overview and Update 394
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 391
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 375
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 369
5HT2B receptor antagonists: a probe for spotting the pharmacophore 330
“Synthesis and α-Adrenoreceptor Blocking Properties of Phenoxybenzamine-Related (2-Chloroethyl)-(2,3-dihydrobenzo-[1,4] dioxin-2-ylmethyl)-(2-phenoxyethyl) Amines”. 311
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 307
Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in Δ16HER2 transgenic mice 301
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 298
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 297
Synthesis and pharmacological profile of a series of 1-substituted-2-carbonyl derivatives of diphenidol: novel M4 muscarinic receptor antagonists 296
4-(4-Fluorobenzoyl)-1-[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]piperidine and its derivatives: synthesis and affinity at 5-HT2A, 5-HT2B and 5-HT2c serotonin receptors 295
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 288
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 280
Synthesis and antimuscarinic activity of derivatives of 2-substituted-1,3-dioxolanes 279
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 277
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 276
Synthesis and alpha1-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin 265
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 265
"[4-[[N-(3-Chlorophenyl)carbamoyl]-2-butynyl]-trimethylammonium (McN-A-343)-Related Compounds. Effect of the Butynyl Chain Inclusion into an Aromatic Unit of the Potency for Muscarinic Receptors 259
Benzimidazole, benzoxazole and benzothiazole derivatives as 5HT(2B) receptor ligands. Synthesis and preliminary pharmacological evaluation 257
Choline-Containing Phospholipids: Structure-Activity Relationships Versus Therapeutic Applications. 257
Design, synthesis and muscarinic activity of deoxamuscarine-related derivatives 257
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 257
“New Pyridazinones: Synthesis and Correlation Between Structure and α-Blocking Activity”. 255
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 254
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 249
14th Camerino-Noordwijkerhout Symposium - Ongoing Progress in Receptor Chemistry 248
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 248
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 247
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 242
(+)-Cyclazosin derivatives as α1-adrenoceptor antagonists 242
Chiral analogues of (+)-cyclazosin as potent α1B-adrenoceptor selective antagonist 242
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 241
Structure-Activity Relatioships Among Novel Phenoxybenzamine-Related Beta-Chloroethylamines. 241
(+)-Cyclazosin, a selective alpha1B-adrenoceptor antagonist: Functional evaluation in rat and rabbit tissues 241
Deoxamuscaroneoxime Devatives as useful Muscarinic Aginist to Explore the Muscarinic Subsite: Demox, Amodulator of Orthosteric and Allosteric Site at Cardiac Muscarinic M2 Receptors. 240
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 239
Antiviral properties of deazaadenine nucleoside derivatives 237
(2,2-Diphenyl-[1,3]oxathiolan-5-ylmethyl)-(3-phenyl-propyl)-amine: a Potent and Selective 5-HT1A Receptor Agonist 235
New sensible method to quantize the intestinal absorption of receptor ligands 235
Synthesis and structure-activity relationships of novel arylpiperazines as potent antagonists of α1-adrenoceptor 233
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 232
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 232
Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives 232
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 231
Determination of Muscarinic Agonist Potencies at M1 and M2 Muscarinic Receptors in a Modified Pithed rat Preparation 230
Analogues of Prazosin That Bear a Benextramine-Related Polyamine Backbone Exhibit Different Antagonism toward alpha1-Adrenoceptor Subtypes 229
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 229
Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds 227
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes 226
Synthesis and antagonistic activity at muscarinic receptor subtypes of some derivatives of diphenidol 226
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 226
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 224
Simplified analogues of Ritanserin and their affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors 222
Adenosine receptor modeling: what does the A2A crystal structure tell us? 221
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 221
Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine 221
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 219
“Synthesis and Pharmacological Evaluation of Enantiomerically Pure 4-Deoxy-4-Fluoro-Muscarines”. 219
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 218
Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine 217
16th Camerino-Noordwijkerhout Symposium - An Overview of Receptor Chemistry 217
Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 3. Effect of inserting the tetraamine backbone into a macrocyclic structure 216
Molecular modulation of muscarinic antagonists. Synthesis and affinity profile of 2,2-diphenyl-2-ethylthio-acetic acid esters designed to probe the binding site cavity. 215
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 215
“Dialkylaminoalkyl Esters of 2,2 Diphenyl-2-Alkylthioacetic Acids: A New Class of Potent and Functionally Selective Muscarinic Antagonists”. 214
Synthesis and α1-antagonist activity of derivatives of 4-chloro-5-{4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl}-3(2H)-pyridazinone 214
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 213
“N,N-diethylaminoethanol and N-methyl-4-piperidinol Esters of 2,2-diphenyl-2-Ethylthioacetic Acid as Potent and Selective Muscarinic Antagonist”. 212
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 211
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 209
Synthesis and pharmacological characterization of enantiomerically pure muscarinic agonists: difluoromuscarines 208
Synthesis and pharmacological characterization of chiral pyrrolidinylfuran derivatives: The discovery of new functionally selective muscarinic agonists 208
Alpha(2)-adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole 208
“Synthesis and Pharmacological Activity of Some New Pyridazinones”. 207
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 207
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease 206
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 205
Highly chiral muscarinic ligands: The discovery of (2S,2 ' R,3 ' S,5 ' R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M-2 partial agonist 204
Synthesis and pharmacological characterization of new chiral derivatives of muscarine and allo-muscarine 201
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 201
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure 200
“Synthesis and α1-Antagonist Activity of New Prazosin-and Benextramine-Related Tetraamine Disulfides”. 200
“Pharmacological Characterization of Muscarinic Receptor Subtypes in Rabbit Isolated Tissue Preparations” 198
Molecular modulation of muscarinic antagonists. Synthesis and pharmacological profile of 2,2-diphenyl-2-ethylthioacetic and 3,3-diphenyl-3-ethylthiopropionic acid derivatives characterized by a dipeptide spacer. 198
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 197
Structure-affinity/activity relationships of 1,4-dioxa-spiro[4.5]decane based ligands at α1 and 5-HT1A receptors 197
Searching for cyclazosin analogues as alfa1B-adrenoceptor antagonists 196
Totale 27.067
Salva come PNG Salva come JPEG
Categoria #
all - tutte 147.427
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.427
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.271 0 0 0 103 99 65 100 154 145 228 147 230
2022/20232.322 257 120 84 384 260 312 13 146 385 121 170 70
2023/20241.769 252 102 112 59 71 115 86 103 198 70 63 538
2024/20255.716 203 146 485 264 159 340 639 1.449 429 403 399 800
2025/20269.332 534 593 1.706 1.137 959 660 1.363 583 546 520 447 284
2026/20272.830 586 378 723 1.143 0 0 0 0 0 0 0 0
Totale 38.700